10/607563

Paul's search

```
=> b reg
FILE 'REGISTRY' ENTERED AT 14:26:56 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 SEP 2006  HIGHEST RN 908228-18-2
DICTIONARY FILE UPDATES:  21 SEP 2006  HIGHEST RN 908228-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d ide can l17 tot

L17  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   642457-84-9  REGISTRY
ED   Entered STN:  28 Jan 2004
CN   1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-
     (trifluoromethyl)phenyl]- (9CI)  (CA INDEX NAME)
MF   C18 H16 Cl F3 N6
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  140:94064


=> d que sta l22
L20             STR
```



VAR G1=N/O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L22 8 SEA FILE=REGISTRY SSS FUL L20

100.0% PROCESSED 218 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

=> => b hcap
FILE 'HCAPLUS' ENTERED AT 14:29:53 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 21 Sep 2006 (20060921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr retable l32 tot

L32 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20683 HCAPLUS Full-text
DN 140:94064
TI Preparation of cyanoiminopiperazines for treating pain
IN **Kyle, Donald J.; Sun, Qun; Tafesse, Laykea;**
Zhang, Chongwu; Zhou, Xiaoming
PA **Euro-Celtique**, S. A., Luxembourg

SO PCT Int. Appl., 287 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004002983	A2	20040108	2003WO-US20509	20030627 <--
	WO2004002983	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2491079	AA	20040108	2003CA-2491079	20030627 <--
	AU2003247829	A1	20040119	2003AU-0247829	20030627 <--
	US2004106625	A1	20040603	2003US-0607563	20030627 <--
	BR2003012322	A	20050412	2003BR-0012322	20030627 <--
	EP---1556354	A2	20050727	2003EP-0762220	20030627 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1678585	A	20051005	2003CN-0820137	20030627 <--
	JP2005535731	T2	20051124	2004JP-0549842	20030627 <--
	NO2005000371	A	20050317	2005NO-0000371	20050124 <--
PRAI	2002US-391962P	P	20020628	<--	
	2002US-411030P	P	20020917	<--	
	2002US-413148P	P	20020925	<--	
	2002US-416582P	P	20021008	<--	
	2003WO-US20509	W	20030627		

OS MARPAT 140:94064
GI



I



II

AB The title compds. [I; A = NR4, O, S; R1 = halo, Me, NO2, CN, etc.; R2 = halo, CN, alkyl, aryl, etc.; R3 is not defined; R4 = alkyl, alkoxy; R6 = Ph, naphthyl, cycloalkyl, etc.; n = 0-3; m = 0-2], useful for treating or preventing pain, urinary incontinence, ulcer, inflammatory bowel disease, irritable bowel syndrome, addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, seizure, a pruritic condition, psychosis, cognitive disorder, memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, muscle spasm, migraine, vomiting, dyskinesia or depression in an animal, were prepared Thus, reacting 2-(1-cyclohexenyl)ethylamine with diphenylcyanocarbodimidate in 2-methoxyethyl ether followed by addition of (R)-1-(3-chloropyridin-2-yl)-3-methylpiperazine afforded II which showed IC50 of 59.4±13.1 nM in capsaicin-based VR1 assay. Ths compds. I were tested for binding to mGluR5, mGluR1, and to VR1. The pharmaceutical composition comprising the compound I is claimed.

IT **642457-82-7P 642457-83-8P 642457-84-9P**
642457-85-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyanoiminopiperazines for treating pain)

RN 642457-82-7 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-83-8 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-84-9 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-85-0 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[2-(1-cyclohexen-1-yl)ethyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:171686 HCAPLUS Full-text
DN 136:232324

TI Preparation of antiviral and antimicrobial substituted guanidines or biguanidines
IN Shetty, B. Vithal
PA USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002017916	A1	20020307	2001WO-US26150	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6699989	B1	20040302	2000US-0649014	20000828
	AU2001086604	A5	20020313	2001AU-0086604	20010822
	EP---1406619	A1	20040414	2001EP-0966061	20010822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US2004132993	A1	20040708	2003US-0720441	20031125
PRAI	2000US-0649014	A1	20000828		
	2001WO-US26150	W	20010822		

OS MARPAT 136:232324
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanidine and biguanidine derivs. of formulas I-V [X = B or CRB; R = H or alkyl and B = (un)substituted alkyl, alkyl-X1-alkyl where X1 = O, S, sulfoxide, tris(2-aminoethyl)amine, N optionally substituted with NHC(NH)NHC(NH)A, (un)substituted heterocycle, (un)substituted-aryl, -cyclohexane, etc.; A = independently H, CN, amino, quinolone, azaquinolone, morpholine, (un)substituted piperazine, (un)substituted aminoadamantane, etc.; Z = C(NH)NHC(NH)A; X2 = (un)substituted-alkyl, -aryl, -heterocycle, or bond; X3 = (CH2)n where n = 1-5; Y1 and Y2 independently = (un)substituted-alkyl, -aryl, -heterocycle, or bond; T = H, alkyl, (un)substituted-aryl, -heterocycle; m = 0-12; p = 0-8] are prepared and disclosed as anti-viral and anti-bacterial agents. Thus, VI was prepared via substitution of 7-chloro-6-fluoro-1,4-dihydro-4-oxo-7-(1- piperazinyl)-quinoline carboxylic acid with piperazine and subsequent addition to hexamethylene bis(cyanoguanidine). VI was found active against HIV at concns. greater than 3.2μg/mL in peripheral blood mononuclear cell assay. Also disclosed are pharmaceutical compns. containing I-V as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compds.

IT **402930-32-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)

RN 402930-32-9 HCAPLUS
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Harris, R	1981	34	623	Australian Journal o	HCAPLUS

L32 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:205054 HCAPLUS Full-text
DN 110:205054
TI 5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents
AU Meyer, Walter E.; Tomcufcik, Andrew S.; Chan, Peter S.; Haug, Margie
CS Lederle Lab., Am. Cyanamid Co., Pearl River, NY, 10965, USA
SO Journal of Medicinal Chemistry (1989), 32(3), 593-7
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 110:205054
GI



AB A series of 5-(1-piperazinyl)-1H-1,2,4-triazol-3-amines was synthesized and screened for antihypertensive and diuretic activity in spontaneously hypertensive rats (SHR). One compound, 5-[4-[(3-chlorophenyl)methyl]-1- piperazinyl]-1H-1,2,4-triazol-3-amine (I), was selected to define the mechanism of its antihypertensive activity. Studies in spontaneously hypertensive rats suggest ganglionic blocking activity. Short-lived antihypertensive activity was observed in conscious renal hypertensive dogs. Structure-activity relationships are discussed. None of the prepared and tested compds. had diuretic activity.

IT **118630-52-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with hydrazine hydrate)

RN 118630-52-7 HCAPLUS
CN 1-Piperazinecarboximidothioic acid, N-cyano-4-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:30:20 ON 22 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:30:20 ON 22 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l28 tot

L28 ANSWER 1 OF 3 USPATFULL on STN
AN 2004:172829 USPATFULL Full-text
TI Antiviral and antimicrobial guanidine or biguanidine derivatives
IN Shetty, B. Vithal, Germantown, MD, UNITED STATES
PI US2004132993 A1 20040708
AI 2003US-0720441 A1 20031125 (10)
RLI Continuation of Ser. No. 2000US-0649014, filed on 28 Aug 2000, GRANTED, Pat. No. US---6699989
DT Utility
FS APPLICATION
LREP ROTHWELL, FIGG, ERNST & MANBECK, P.C., 1425 K STREET, N.W., SUITE 800, WASHINGTON, DC, 20005
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **402930-32-9P**
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)
RN 402930-32-9 USPATFULL
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L28 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:139449 USPATFULL Full-text
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
Zhang, Chongwu, Dayton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES
PI US2004106625 A1 20040603
AI 2003US-0607563 A1 20030627 (10)
PRAI 2002US-391962P 20020628 (60)
2002US-411030P 20020917 (60)
2002US-413148P 20020925 (60)
2002US-416582P 20021008 (60)
DT Utility
FS APPLICATION

LREP JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113
CLMN Number of Claims: 236
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula: ##STR1##

wherein A, Ar, R.sup.3, R.sup.6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **642457-82-7P 642457-83-8P 642457-84-9P**
642457-85-0P
(preparation of cyanoiminopiperazines for treating pain)
RN 642457-82-7 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-83-8 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-84-9 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-85-0 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[2-(1-cyclohexen-1-yl)ethyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L28 ANSWER 3 OF 3 USPATFULL on STN
AN 2004:53414 USPATFULL Full-text
TI Antiviral and antimicrobial guanidine or biguanidine derivatives
IN Shetty, B. Vithal, 14438 Long Channel Cir., Germantown, MD, United States 20874
PI US---6699989 B1 20040302
AI 2000US-0649014 20000828 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Rothwell, Figg, Ernst & Manbeck, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **402930-32-9P**
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)
RN 402930-32-9 USPATFULL
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr l27 tot

L27 ANSWER 1 OF 1 USPATFULL on STN
AN 2004:139449 USPATFULL Full-text
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES

Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
Zhang, Chongwu, Dayton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES

PI US2004106625 A1 20040603
AI 2003US-0607563 A1 20030627 (10)
PRAI 2002US-391962P 20020628 (60)
2002US-411030P 20020917 (60)
2002US-413148P 20020925 (60)
2002US-416582P 20021008 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113
CLMN Number of Claims: 236
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula: ##STR1##

wherein A, Ar, R.sup.3, R.sup.6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **642457-84-9P**
(preparation of cyanoiminopiperazines for treating pain)
RN 642457-84-9 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:17:24 ON 22 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 14:17:29 ON 22 SEP 2006
L1 1 US2004106625/PN OR (US2003-607563 OR US2002-411030# OR US2002-3
E KYLE D/AU
L2 203 E3-10,E26-32
E SUN Q/AU
L3 289 E3-15
E SUN QUN/AU
L4 241 E3-14
E TAFESSE L/AU
L5 22 E3-4
E ZHANG C/AU
L6 1895 E3-26
E ZHANG CHONG/AU

```
L7            62 E3,E20
                 E ZHANG CHONGWU/AU
L8            11 E3
                 E ZHOU X/AU
L9          1511 E3-27
                 E ZHOU XIAO/AU
L10          138 E3,E57
                 E ZHOU XIAOMING/AU
L11           96 E3
L12            0 (EURO CHELTIQUE)/CS,PA
L13          259 (EURO CELTIQUE)/CS,PA

     FILE 'REGISTRY' ENTERED AT 14:22:09 ON 22 SEP 2006

     FILE 'HCAPLUS' ENTERED AT 14:22:09 ON 22 SEP 2006
L14             TRA L1 1- RN :       12 TERMS

     FILE 'REGISTRY' ENTERED AT 14:22:10 ON 22 SEP 2006
L15           12 SEA L14
L16            5 L15 AND NC5/ES AND NC2NC2/ES
L17            1 C18H16CLF3N6 AND NC5/ES AND NC2NC2/ES

     FILE 'HCAPLUS' ENTERED AT 14:23:36 ON 22 SEP 2006
L18            1 L17
L19            1 L18 AND L1-13

     FILE 'REGISTRY' ENTERED AT 14:23:44 ON 22 SEP 2006
L20              STR
L21            0 L20
L22            8 L20 FULL
                 SAV TEM WAR563F0/A L22

     FILE 'HCAPLUS' ENTERED AT 14:27:09 ON 22 SEP 2006
L23            3 L22
L24            1 L23 AND L1-13
L25            2 L23 NOT L24

     FILE 'HCAOLD' ENTERED AT 14:27:46 ON 22 SEP 2006
L26            0 L22,L17

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:27:54 ON 22 SEP 2006
L27            1 L17
L28            3 L22

     FILE 'MEDLINE' ENTERED AT 14:28:22 ON 22 SEP 2006
L29            0 L26

     FILE 'EMBASE' ENTERED AT 14:28:36 ON 22 SEP 2006
L30            0 L29

     FILE 'BIOSIS' ENTERED AT 14:28:42 ON 22 SEP 2006
L31            0 L29

     FILE 'HCAPLUS' ENTERED AT 14:29:13 ON 22 SEP 2006
L32            3 L19,L23-25

=>
```

```
=> b reg
FILE 'REGISTRY' ENTERED AT 14:26:56 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 SEP 2006  HIGHEST RN 908228-18-2
DICTIONARY FILE UPDATES:  21 SEP 2006  HIGHEST RN 908228-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d ide can l17 tot

L17  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   642457-84-9  REGISTRY
ED   Entered STN:  28 Jan 2004
CN   1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-
     (trifluoromethyl)phenyl]- (9CI)  (CA INDEX NAME)
MF   C18 H16 Cl F3 N6
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  140:94064


=> d que sta l22
L20              STR
```



VAR G1=N/O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L22 8 SEA FILE=REGISTRY SSS FUL L20

100.0% PROCESSED 218 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

=> => b hcap
FILE 'HCAPLUS' ENTERED AT 14:29:53 ON 22 SEP 2006

FILE COVERS 1907 - 22 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 21 Sep 2006 (20060921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr retable l32 tot

L32 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

noble jarrell 22/09/2006

AN 2004:20683 HCAPLUS
DN 140:94064
TI Preparation of cyanoiminopiperazines for treating pain
IN **Kyle, Donald J.; Sun, Qun; Tafesse, Laykea; Zhang, Chongwu; Zhou, Xiaoming**
PA **Euro-Celtique, S. A., Luxembourg**
SO PCT Int. Appl., 287 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004002983	A2	20040108	2003WO-US20509	20030627 <--
	WO2004002983	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2491079	AA	20040108	2003CA-2491079	20030627 <--
	AU2003247829	A1	20040119	2003AU-0247829	20030627 <--
	US2004106625	A1	20040603	2003US-0607563	20030627 <--
	BR2003012322	A	20050412	2003BR-0012322	20030627 <--
	EP---1556354	A2	20050727	2003EP-0762220	20030627 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1678585	A	20051005	2003CN-0820137	20030627 <--
	JP2005535731	T2	20051124	2004JP-0549842	20030627 <--
	NO2005000371	A	20050317	2005NO-0000371	20050124 <--
PRAI	2002US-391962P	P	20020628	<--	
	2002US-411030P	P	20020917	<--	
	2002US-413148P	P	20020925	<--	
	2002US-416582P	P	20021008	<--	
	2003WO-US20509	W	20030627		

OS MARPAT 140:94064
GI



I



II

AB The title compds. [I; A = NR4, O, S; R1 = halo, Me, NO2, CN, etc.; R2 = halo, CN, alkyl, aryl, etc.; R3 is not defined; R4 = alkyl, alkoxy; R6 = Ph, naphthyl, cycloalkyl, etc.; n = 0-3; m = 0-2], useful for treating or preventing pain, urinary incontinence, ulcer, inflammatory bowel disease,

noble jarrell 22/09/2006

irritable bowel syndrome, addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, seizure, a pruritic condition, psychosis, cognitive disorder, memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, muscle spasm, migraine, vomiting, dyskinesia or depression in an animal, were prepared Thus, reacting 2-(1-cyclohexenyl)ethylamine with diphenylcyanocarbodimidate in 2-methoxyethyl ether followed by addition of (R)-1-(3-chloropyridin-2-yl)-3-methylpiperazine afforded II which showed IC50 of 59.4±13.1 nM in capsaicin-based VR1 assay. Ths compds. I were tested for binding to mGluR5, mGluR1, and to VR1. The pharmaceutical composition comprising the compound I is claimed.

IT **642457-82-7P 642457-83-8P 642457-84-9P 642457-85-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyanoiminopiperazines for treating pain)

RN 642457-82-7 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-83-8 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-84-9 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-85-0 HCAPLUS
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[2-(1-cyclohexen-1-yl)ethyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

noble jarrell 22/09/2006



L32 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:171686 HCAPLUS
DN 136:232324
TI Preparation of antiviral and antimicrobial substituted guanidines or biguanidines
IN Shetty, B. Vithal
PA USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002017916	A1	20020307	2001WO-US26150	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6699989	B1	20040302	2000US-0649014	20000828
	AU2001086604	A5	20020313	2001AU-0086604	20010822
	EP---1406619	A1	20040414	2001EP-0966061	20010822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US2004132993	A1	20040708	2003US-0720441	20031125
PRAI	2000US-0649014	A1	20000828		
	2001WO-US26150	W	20010822		

OS MARPAT 136:232324
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanidine and biguanidine derivs. of formulas I-V [X = B or CRB; R = H or alkyl and B = (un)substituted alkyl, alkyl-X1-alkyl where X1 = O, S, sulfoxide, tris(2-aminoethyl)amine, N optionally substituted with NHC(NH)NHC(NH)A, (un)substituted heterocycle, (un)substituted-aryl, -cyclohexane, etc.; A = independently H, CN, amino, quinolone, azaquinolone, morpholine, (un)substituted piperazine, (un)substituted

noble jarrell 22/09/2006

aminoadamantane, etc.; Z = C(NH)NHC(NH)A; X2 = (un)substituted-alkyl, -aryl, -heterocycle, or bond; X3 = (CH2)n where n = 1-5; Y1 and Y2 independently = (un)substituted-alkyl, -aryl, -heterocycle, or bond; T = H, alkyl, (un)substituted-aryl, -heterocycle; m = 0-12; p = 0-8] are prepared and disclosed as anti-viral and anti-bacterial agents. Thus, VI was prepared via substitution of 7-chloro-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline carboxylic acid with piperazine and subsequent addition to hexamethylene bis(cyanoguanidine). VI was found active against HIV at concns. greater than 3.2μg/mL in peripheral blood mononuclear cell assay. Also disclosed are pharmaceutical compns. containing I-V as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compds.

IT **402930-32-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)

RN 402930-32-9 HCAPLUS
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Harris, R	1981	34	623	Australian Journal o	HCAPLUS

L32 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:205054 HCAPLUS
DN 110:205054
TI 5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents
AU Meyer, Walter E.; Tomcufcik, Andrew S.; Chan, Peter S.; Haug, Margie
CS Lederle Lab., Am. Cyanamid Co., Pearl River, NY, 10965, USA
SO Journal of Medicinal Chemistry (1989), 32(3), 593-7
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 110:205054
GI



I

AB A series of 5-(1-piperazinyl)-1H-1,2,4-triazol-3-amines was synthesized and screened for antihypertensive and diuretic activity in spontaneously hypertensive rats (SHR). One compound, 5-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-1H-1,2,4-triazol-3-amine (I), was selected to define the mechanism of its antihypertensive activity. Studies in spontaneously

hypertensive rats suggest ganglionic blocking activity. Short-lived antihypertensive activity was observed in conscious renal hypertensive dogs. Structure-activity relationships are discussed. None of the prepared and tested compds. had diuretic activity.

IT **118630-52-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with hydrazine hydrate)

RN 118630-52-7 HCAPLUS

CN 1-Piperazinecarboximidothioic acid, N-cyano-4-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:30:20 ON 22 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:30:20 ON 22 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l28 tot

L28 ANSWER 1 OF 3 USPATFULL on STN
AN 2004:172829 USPATFULL
TI Antiviral and antimicrobial guanidine or biguanidine derivatives
IN Shetty, B. Vithal, Germantown, MD, UNITED STATES
PI US2004132993 A1 20040708
AI 2003US-0720441 A1 20031125 (10)
RLI Continuation of Ser. No. 2000US-0649014, filed on 28 Aug 2000, GRANTED, Pat. No. US---6699989
DT Utility
FS APPLICATION
LREP ROTHWELL, FIGG, ERNST & MANBECK, P.C., 1425 K STREET, N.W., SUITE 800, WASHINGTON, DC, 20005
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **402930-32-9P**
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)

noble jarrell 22/09/2006

RN 402930-32-9 USPATFULL
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L28 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:139449 USPATFULL
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
Zhang, Chongwu, Dayton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES
PI US2004106625 A1 20040603
AI 2003US-0607563 A1 20030627 (10)
PRAI 2002US-391962P 20020628 (60)
2002US-411030P 20020917 (60)
2002US-413148P 20020925 (60)
2002US-416582P 20021008 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113
CLMN Number of Claims: 236
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula: ##STR1##

wherein A, Ar, R.sup.3, R.sup.6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **642457-82-7P 642457-83-8P 642457-84-9P**
642457-85-0P
(preparation of cyanoiminopiperazines for treating pain)
RN 642457-82-7 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-83-8 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-84-9 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-85-0 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[2-(1-cyclohexen-1-yl)ethyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L28 ANSWER 3 OF 3 USPATFULL on STN
AN 2004:53414 USPATFULL
TI Antiviral and antimicrobial guanidine or biguanidine derivatives

noble jarrell 22/09/2006

IN Shetty, B. Vithal, 14438 Long Channel Cir., Germantown, MD, United States 20874
PI US---6699989 B1 20040302
AI 2000US-0649014 20000828 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Rothwell, Figg, Ernst & Manbeck, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **402930-32-9P**
(target compound; preparation of antiviral and antimicrobial substituted guanidine or biguanidines)
RN 402930-32-9 USPATFULL
CN 1,6-Naphthyridine-3-carboxylic acid, 7-[4-[(cyanoamino)iminomethyl]-1-piperazinyl]-1-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr l27 tot

L27 ANSWER 1 OF 1 USPATFULL on STN
AN 2004:139449 USPATFULL
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
Zhang, Chongwu, Dayton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES
PI US2004106625 A1 20040603
AI 2003US-0607563 A1 20030627 (10)
PRAI 2002US-391962P 20020628 (60)
2002US-411030P 20020917 (60)
2002US-413148P 20020925 (60)
2002US-416582P 20021008 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113
CLMN Number of Claims: 236
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula: ##STR1##

wherein A, Ar, R.sup.3, R.sup.6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **642457-84-9P**
(preparation of cyanoiminopiperazines for treating pain)
RN 642457-84-9 USPATFULL
CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:17:24 ON 22 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 14:17:29 ON 22 SEP 2006
L1 1 US2004106625/PN OR (US2003-607563 OR US2002-411030# OR US2002-3
E KYLE D/AU
L2 203 E3-10,E26-32
E SUN Q/AU
L3 289 E3-15
E SUN QUN/AU
L4 241 E3-14
E TAFESSE L/AU
L5 22 E3-4
E ZHANG C/AU
L6 1895 E3-26
E ZHANG CHONG/AU
L7 62 E3,E20
E ZHANG CHONGWU/AU
L8 11 E3
E ZHOU X/AU
L9 1511 E3-27
E ZHOU XIAO/AU
L10 138 E3,E57
E ZHOU XIAOMING/AU
L11 96 E3
L12 0 (EURO CHELTIQUE)/CS,PA
L13 259 (EURO CELTIQUE)/CS,PA

FILE 'REGISTRY' ENTERED AT 14:22:09 ON 22 SEP 2006

FILE 'HCAPLUS' ENTERED AT 14:22:09 ON 22 SEP 2006
L14 TRA L1 1- RN : 12 TERMS

noble jarrell 22/09/2006

```
     FILE 'REGISTRY' ENTERED AT 14:22:10 ON 22 SEP 2006
L15            12 SEA L14
L16             5 L15 AND NC5/ES AND NC2NC2/ES
L17             1 C18H16CLF3N6 AND NC5/ES AND NC2NC2/ES

     FILE 'HCAPLUS' ENTERED AT 14:23:36 ON 22 SEP 2006
L18             1 L17
L19             1 L18 AND L1-13

     FILE 'REGISTRY' ENTERED AT 14:23:44 ON 22 SEP 2006
L20               STR
L21             0 L20
L22             8 L20 FULL
                  SAV TEM WAR563F0/A L22

     FILE 'HCAPLUS' ENTERED AT 14:27:09 ON 22 SEP 2006
L23             3 L22
L24             1 L23 AND L1-13
L25             2 L23 NOT L24

     FILE 'HCAOLD' ENTERED AT 14:27:46 ON 22 SEP 2006
L26             0 L22,L17

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:27:54 ON 22 SEP 2006
L27             1 L17
L28             3 L22

     FILE 'MEDLINE' ENTERED AT 14:28:22 ON 22 SEP 2006
L29             0 L26

     FILE 'EMBASE' ENTERED AT 14:28:36 ON 22 SEP 2006
L30             0 L29

     FILE 'BIOSIS' ENTERED AT 14:28:42 ON 22 SEP 2006
L31             0 L29

     FILE 'HCAPLUS' ENTERED AT 14:29:13 ON 22 SEP 2006
L32             3 L19,L23-25

=>
```

noble jarrell 22/09/2006